Holen Sie sich die Stockscreener-App
11.36
0.89%
0.10
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play - TipRanks
Keros Therapeutics to receive $20M milestone from Takeda By Investing.com - Investing.com South Africa
Keros Therapeutics to Receive $20 Million Takeda Milestone Payment - Minichart
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Yahoo Finance
Keros Therapeutics to receive $20M milestone from Takeda - Investing.com
Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial - TipRanks
Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial - Quiver Quantitative
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Yahoo Finance
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages - MarketBeat
Keros Begins Phase 2 Rinvatercept Trial in DMD - TipRanks
The first patient has received a drug being tested for Duchenne muscular dystrophy. Initial data are expected in 2027. - Stock Titan
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
Live Keros Therapeutics, Inc. (KROS) Technical Analysis - Traders Union
Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with 74.59% Upside Potential - DirectorsTalk Interviews
Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026) - Stock Titan
(KROS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bank of New York Mellon Corp Takes $1.11 Million Position in Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics May Offer Up To $350 Million Of SecuritiesSEC Filing - TradingView
Share Buyback Program Approved by Keros Therapeutics (NASDAQ:KROS) Board of Directors - marketbeat.com
Keros Therapeutics (NASDAQ: KROS) Launches $5M Stock Buyback Program Following $20M Milestone from Takeda - kalkinemedia.com
Keros Therapeutics Announces Share Repurchase Authorization Program - TipRanks
Keros Therapeutics Announces $5 Million Share Repurchase Authorization - The Manila Times
Keros approves $5M buyback after $20M Takeda milestone; cash runway into H2 2028 - TradingView
Keros Therapeutics announces $5M share repurchase program after Takeda payment - TipRanks
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Keros Therapeutics Approves $5 Million Share Buyback - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Keros Therapeutics, Inc. authorizes a Buyback Plan. - marketscreener.com
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell" - marketbeat.com
Keros Therapeutics (NASDAQ:KROS): Is Its Pipeline Worth the Risk? - Kalkine Media
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com - Investing.com South Africa
Keros Therapeutics director Bienaime buys $10,270 in shares - Investing.com
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS - MarketBeat
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS - marketbeat.com
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research - marketbeat.com
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com - Investing.com India
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
KROS Q2 2026 Earnings: Wider-than-Expected Net Loss Pressures SharesFull Year Guidance - dars.gov.et
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - Yahoo Finance
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock - MarketBeat
Keros (KROS) Today: Moves 4.95% Down to $10.55 in the Latest Session; Market Levels: $10.02 and $11.08 Define the Nearby Reference Levels in the Available RecordPut Support - vinanet.vn
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale - Stock Titan
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - marketbeat.com
Keros Therapeutics (KROS) Drops 5.25% to $10.1 — Support at $9.59 in FocusEarnings Miss Risk - vinanet.vn
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):